Background Pyoderma gangrenosum (PG) is an uncommon, destructive, cutaneous ulceration, belonging to the neutrophilic disease spectrum. It is associated with systemic disease in 50% of cases.
Introduction
Pyoderma gangrenosum (PG) is an uncommon, destructive, cutaneous ulceration. First described by Brunsting et al. in 1930, 1 it is part of the neutrophilic disease spectrum. It is characterized by a rapidly enlarging necrotic ulceration with an undermined border and a surrounding areola of erythema. Systemic diseases often associated with PG include inflammatory bowel disease, rheumatoid arthritis, hematologic malignancy, and monoclonal immunoglobulin A (IgA) gammapathy.
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Patients and methods
This study reports the results of a retrospective evaluation of 21 cases of PG. All cases studied fulfilled the following criteria: 
Results
Twenty-one patients were diagnosed with PG between January 1981 and December 2000. They had an average age of 41.8 years and the sex ratio was 1.1. The clinical features and associated diseases are summarized in Table 1 .
Patients 11 and 12 suffered from neutrophilic pulmonary involvement. Radiological improvement with corticosteroid therapy was noted in patient 11. Unfortunately, the evolution of the disease was fatal in both cases.
Ulcerated lesions were the most frequent and were noted in 17 cases. The four remaining patients presented with the bullous variant (two cases) and the vegetative variant (two cases).
Histopathology showed vasculitis in 13 patients. Of these, 11 were leukocytoclastic and the others predominantly lymphocytic.
The therapeutic agents used were corticosteroids and clofazimine. A rapid response was noted with the first therapy and a slight improvement with the second. Thirty per cent of patients recovered completely (long-term observation of 3 years). Five patients were lost to follow-up after recovery. The recurrence rate was about 46%.
Discussion
PG is a rare disease. In this study, 21 patients with PG were observed over a 20-year period in three dermatologic departments in Tunis. Its annual incidence in southern Germany has been estimated to be at least two cases per year per 10 6 population. 3 The disease develops in most patients between 25 and 54 years of age. 4 PG is rare in children. 4, 5 Forty-six cases only have been reported in children. 5 Two pediatric cases were found in our study (patients 3 and 4). The first case presented with a multiple PG variant and the second with cryoglobulinemia associated with PG. PG affects men and women equally. 5 The ulcerative variant is the most frequent (Figs 1, 2) . It is frequently associated with arthritis, inflammatory bowel disease, and monoclonal gammopathy. Other reported variants can occur: pustular PG, often associated with acute inflammatory bowel disease, bullous PG, associated with myeloproliferative disorders, and vegetative PG, with usually no associated disease. 4 Typical predilection sites are the lower legs, 3, 4 found in 62% of cases. Fifty-seven per cent of patients suffer from more than one lesion.
The diagnosis of PG rests primarily on the clinical features. Histopathologic changes depend on the type of lesion being studied (ulcerative, vegetative), the stage of evolution of the lesion, and the site from which a biopsy specimen is obtained in a given lesion. 5 The extracutaneous manifestations in PG represent a common denominator of neutrophilic dermatosis, which led Vignon-Pennamen and Wallach 6 to suggest the unifying concept of "neutrophilic disease" comprising both cutaneous and extracutaneous manifestations.
The condition may affect many internal organs, notably the lungs, the joints, and the digestive tract. Marie et al. 7 described the case of a patient with PG in whom a severe sterile neutrophilic myositis developed as the first manifestation of acute myelogenous leukemia.
Extracutaneous manifestations may be a sign of associated pathology, in particular hematologic pathology, and clinicians must be aware of this possibility. Twelve cases of PG with pulmonary manifestations have been reported in the literature; we can add two others (patients 11 and 12). 5, [8] [9] [10] Various associated diseases were found in over half of the patients studied in this report: ulcerative colitis, Crohn's disease, rheumatoid arthritis with Gougerot-Sjögren syndrome, leukemia, and B lymphoma with monoclonal gammopathy. Other associated diseases, less frequently reported in the literature, were found in our study, including Takayashu arteritis, suppurativa hidradenitis, cryoglobulinemia, and autoimmune anemia.
The diagnosis of PG must be followed by a meticulous exploration for a morbid associated disease, whose control can in some cases favor the recovery of cutaneous lesions. 2 The treatment of PG is often empirical, because of the lack of randomized controlled trials. Recent lesions can regress with topical or intralesional corticosteroids. 4 For aggressive lesions, systemic corticotherapy is the most appropriate agent. Sulfones, clofazimine, and cyclines represent some interesting alternative therapies, and are used alone or in relay to corticosteroids. Immunosuppressors, such as azathioprine, cyclophosphamide, cyclosporine, and tacrolimus, appear to be very useful in recalcitrant forms of PG. Some authors have reported success in treating patients with the ulcerative variant of PG with bioengineered skin and cyclosporine.
11 Thalidomide has dramatically improved some patients with PG unresponsive to prednisone, minocycline, and clofazimine. [12] [13] [14] The evolution of PG is extremely variable with the alternation of flares and recovery over several months or years. Patients affected by PG associated with hematologic diseases have a worse prognosis.
The recurrence rate in our patients was about 46% regardless of the treatment prescribed. Neutrophilic lung involvement was fatal in two patients. 
